Zilbesarian, an RNA Interference Agent, Shows Promise for Hypertension in Phase 1 Trial
A multipart, phase 1 trial provides evidence demonstrating the safety of zilbesarian, an RNA interference agent, which appeared to have a favorable safety profile among adult patients with hypertension.
United Kingdom United States Simon Fox Akshay Desai Heart Failure Program Alnylam Pharmaceuticals Inc
Source: hcplive.com